IP Library Granted Patent US 11,026,972
Granted Patent B2
US 11,026,972 · App. 16/156,146 · Granted Jun 8, 2021

Methods for generating macrophages with enhanced cancer phagocytosis

Inventors: Yuan Liu (Decatur, GA); Zhen Bian (Atlanta, GA); Ke Zen (Decatur, GA)
Assignee: Georgia State University Research Foundation, Inc.
A61K35/15A61K31/7088A61K31/739A61K38/19A61K38/191A61K38/204A61K38/2006A61K39/395A61K45/06A61P35/00C07K16/244C07K16/2896C12N5/0645C12N15/1138A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,026,972
App. No.
16/156,146
Granted
Jun 8, 2021
Kind
B2
Abstract

The present invention relates to compositions and methods variously useful in treating cancer, inhibiting graft rejection, and treating autoimmune disease. The compositions and methods include those in which macrophages are conditioned to down regulate or upregulate the expression or activity of SIRPα or its interaction with CD47.

Claims (14)

1. A method of generating macrophages with enhanced cancer phagocytosis, the method comprising:

(a) providing a biological sample from a subject, wherein the biological sample comprises macrophages;

(b) exposing the sample to an effective amount of a first composition comprising at least 100 units/ml IFNγ to suppress the expression or activity of signal regulatory protein α (SIRPα); and

(c) exposing the sample from step (b) to an effective amount of a second composition that activates Protein kinase C (PKC)-Spleen tyrosine kinase (Syk) pathway, thereby generating macrophages with enhanced cancer phagocytosis.

2. The method of claim 1 , wherein the biological sample further comprises cancer cells.

3. The method of claim 1 , wherein the biological sample further comprises dendritic cells.

4. The method of claim 1 , wherein the biological sample has been enriched for myeloid cells.

5. The method of claim 1 , wherein the first composition further comprises a Toll-like receptor (TLR) ligand.

6. The method of claim 5 , wherein the TLR ligand comprises a CpG oligonucleotide or a polyinosinic:polycytidylic acid (poly I:C).

7. The method of claim 5 , wherein the TLR ligand comprises GARDIQUIMOD or IMIQUIMOD.

8. The method of claim 1 , wherein the first composition further comprises, IL-6.

9. The method of claim 1 , wherein the first composition comprises a Toll-like receptor (TLR) ligand, IFNγ, and IL-6.

10. The method of claim 1 , wherein the second composition comprises phorbol 12-myristate 13-acetate (PMA).

11. The method of claim 1 , further comprising administering the macrophages with enhanced cancer phagocytosis to a subject.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 6, 2019
From: GEORGIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049087/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2019
From: LIU, YUAN; BIAN, ZHEN; ZEN, KE
To: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 048136/0194 →
Continuity (4)
Continuation In Part PCTUS2017026821 · Apr 10, 2017
Provisional Application 62320588 · Apr 10, 2016
Provisional Application 62379454 · Aug 25, 2016
Related Publication 20190134089A1 · May 9, 2019